Vijayakumar Ramakrishnan

Vijayakumar Ramakrishnan

Auto-generated profile, based on publicly available information

Vijayakumar Ramakrishnan

Department of Pharmaceutics, Faculty of Pharmacy, Karpagam College of Pharmacy, Coimbatore, Tamil Nadu,641021, India

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2026 in Current Respiratory Medicine Reviews
Verified
Journal Article
Closed access
PDF file
SKSriram K
Sriram K
PVPrabhakar V
Prabhakar V
PNPreethi N
Preethi N
VRVijayakumar Ramakrishnan
Vijayakumar Ramakrishnan
TPThilagesh P
Thilagesh P
SMShankar Ganesh M
Shankar Ganesh M
Introduction: Pulmonary tuberculosis (PTB) and nontuberculous mycobacterial pulmonary disease (NTM-PD) often require prolonged multidrug therapy because phenotypically tolerant and persistent bacilli survive within heterogeneous pulmonary niches despite genetic susceptibility. This review evaluates mechanisms underlying these non-heritable survival states and therapeutic strategies that may improve sterilizing cure. Methods: Literature from 2000 to March 2026 was searched in PubMed/MEDLINE, ScienceDirect, Embase, Scopus, Web of Science, and ClinicalTrials.gov. Mechanistic, translational, pharmacological, clinical, and guideline studies addressing dormancy, biofilms, intracellular persistence, lesion pharmacology, efflux, metabolic adaptation, host-directed therapy, and pulmonary drug delivery were narratively synthesized. Results: Hypoxic, acidic, nutrient-limited, lipid-rich caseous, intracellular, and mucus/biofilmassociated environments create spatial and metabolic heterogeneity that slows bacillary killing without necessarily increasing the minimum inhibitory concentration. Persistence is sustained by DosRlinked adaptation, respiratory and ATP dependence, altered envelope permeability, adaptive efflux, macrophage conditioning, and biofilm architecture. Persister-active combinations, respiratory-chain inhibition, biofilm disruption, host-directed adjuncts, inhaled/liposomal delivery, and lesionpenetrant optimization are the most promising approaches. Discussion: Current susceptibility testing and plasma-based exposure measures incompletely represent protected pulmonary compartments, and validated clinical biomarkers of persister burden remain limited. Future trials should prioritize compartment-aware pharmacology and relapse-free sterilization endpoints. Conclusion: Durable cure will likely require combining susceptibility-guided therapy with strategies that eradicate phenotypically tolerant bacilli across pulmonary niches.